XOMA (NASDAQ:XOMA) Stock Rating Upgraded by StockNews.com

XOMA (NASDAQ:XOMA) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $123.00 target price on shares of XOMA in a report on Tuesday, January 7th.

XOMA Stock Performance

Shares of NASDAQ XOMA opened at $28.12 on Thursday. The company has a 50 day simple moving average of $28.81 and a two-hundred day simple moving average of $28.02. The stock has a market cap of $331.34 million, a price-to-earnings ratio of -8.08 and a beta of 0.92. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a 12 month low of $18.57 and a 12 month high of $35.00.

Insider Buying and Selling at XOMA

In other XOMA news, CEO Owen Hughes sold 21,881 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the sale, the chief executive officer now directly owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. This trade represents a 38.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.20% of the stock is owned by corporate insiders.

Institutional Trading of XOMA

Institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets raised its position in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares during the last quarter. Rhumbline Advisers lifted its position in shares of XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after acquiring an additional 1,334 shares in the last quarter. Barclays PLC boosted its stake in shares of XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after acquiring an additional 8,447 shares during the last quarter. Ellsworth Advisors LLC purchased a new stake in shares of XOMA during the third quarter worth approximately $516,000. Finally, Bank of New York Mellon Corp increased its position in shares of XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after purchasing an additional 1,968 shares in the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.